For Immediate Release
FDA Rule Improves Labeling of Medications Used During Pregnancy and Lactation
Contact: Kathryn Ryan
New Rochelle, NY, June 15, 2017—The new U.S. Food and Drug Administration's (FDA's) Pregnancy and Lactation Labeling Rule should help healthcare providers better explain to pregnant and breastfeeding patients the benefits and risks of taking a specific medication. The new labeling format provides a summary of the evidence-based risks, replacing the previous that were too often misinterpreted, according to an article published in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Pediatric Allergy, Immunology, and Pulmonology website.
Miriam Dinatale, DO, Leyla Sahin, MD, Tamara Johnson, MD, Tammie Brent Howard, RN, and Lynne Yao, MD, Food and Drug Administration, Silver Spring, MD, present a clear description of the new FDA labeling rule, how it is being implemented, and how it improves on the existing labeling system in the article entitled "Medication Use During Pregnancy and Lactation: Introducing the Pregnancy and Lactation Labeling Rule." More than half of pregnant women report taking at least one medication. These new labeling requirements detail the risks of a prescription drug or biological product for the mother, fetus, breastfeeding infant, and women and men of reproductive potential.
"According to a recent study by the Centers for Disease Control and Prevention (CDC) on Family Growth in the U.S., approximately 50% of women between ages 15 and 44 responded that they intend to have a child in the future. Healthcare providers responsible for counseling patients who are pregnant, planning to become pregnant, and those who are breastfeeding need a reliable source of information about prescription medications," says Pediatric Allergy, Immunology, and Pulmonology Editor-in-Chief Mary Cataletto, MD, Professor of Clinical Pediatrics, Stony Brook University School of Medicine. "The new labeling requirement provides a more user-friendly presentation of studies, registries, and available information that can be used to assist providers in discussing medication risks and benefits with their patients."
About the Journal
Pediatric Allergy, Immunology, and Pulmonology is a quarterly, peer-reviewed journal published online with open access options and in print that synthesizes the pulmonary, allergy, and immunology communities in the advancement of the respiratory health of children. Led by Editor-in-Chief Mary Cataletto, MD, Professor of Clinical Pediatrics, State University of New York at Stony Brook, the Journal provides comprehensive coverage to further the understanding and optimize the treatment of some of the most common and costly chronic illnesses in children. It includes original translational, clinical, and epidemiologic research; public health, quality improvement, and case control studies; patient education research; and the latest research and standards of care for functional and genetic immune deficiencies and interstitial lung diseases. Tables of content and a sample issue may be viewed on the Pediatric Allergy, Immunology, and Pulmonology website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug Delivery, Breastfeeding Medicine, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.